Interview with Harry Flore, CEO, HAL Allergy Group
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
Address: J.H. Oortweg 15-17
2333 CH Leiden,Netherlands
Tel: +31-88-1959 000
Web: http://www.hal-allergy.com/
HAL stands for ‘Haarlems Allergenen Laboratorium’, an originally Dutch company set up in Haarlem over 50 years ago. A lot has happened since then. HAL Allergy has grown into a company of international repute that operates in as many as 15 countries. Our products are supplied to major European countries, such as Germany, Austria, Italy, the Benelux, Spain and Greece.
We take more than a little pride in our leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes. Our head office, which houses the development, production, quality control, clinical and registration departments, has a staff of approximately 180. HAL Allergy works intensively with its foreign branches and prominent research institutes, thus optimally combining knowledge and experience. Our aim is to continuously improve ways of diagnosing, treating and curing allergies.
Our meetings frequently bring us here to the Leiden Bio Science Park, but more often than not, to meet with younger, up-and-coming companies. HAL Allergy, meanwhile, has a rich and…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed…
John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how…
As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception…
Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
See our Cookie Privacy Policy Here
